Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chinoy, Hector
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.	Recruiting	2/3	240	Europe, Canada, Japan, US, RoW	EFG PH20 SC, PBO	argenx, argenx BV	Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome	12/26	02/27
MYOJAK, NCT04208464 / 2019-003868-42: JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM	Completed	2a	15	Europe	Baricitinib	University of Manchester, Eli Lilly and Company, Clinical Trials Unit, Manchester, Karolinska Institutet	Idiopathic Inflammatory Myopathies	09/23	09/23